1. Pink Sheet
  2. >>Pathways & Standards

Lilly’s Thanksgiving Turkey: Lessons From Another Failed Alzheimer’s Program

 
• By Michael McCaughan

There was nothing to be thankful about from Lilly’s disclosure that its potential Alzheimer’s therapy solanezumab failed to demonstrate significant improvement in cognition in a third large Phase III trial. But it does reinforce the wisdom of FDA’s standards for subgroup analysis in failed trials.

formula

Eli Lilly & Co.’s day-before-Thanksgiving disclosure that its EXPEDITION3 trial of the potential Alzheimer’s therapy solanezumab failed to meet its primary endpoint didn’t give anyone reason to feel thankful over the long holiday weekend.

It was particularly bad news for Lilly, of course, whose massive investment in the project all goes for naught. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards

US FDA’s CoGenT Pilot At Risk? Project Orbis Success May Not Save Cell/Gene Therapy Initiative

 
• By Bridget Silverman

Despite following the path of the popular Project Orbis, the cell and gene therapy international collaborative review pilot is being reconsidered by the FDA's new management.

Kisunla Back In The Spotlight As EMA Reconsiders Alzheimer’s Drug Rejection

 
• By Eliza Slawther

It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.

Alzheimer’s Drug Leqembi May Be On Course To India, Kisunla In The Wings

 
• By Anju Ghangurde

Key expert panel go-ahead with a trial waiver put’s Eisai's Alzheimer's therapy on track for a debut in India where tailored pricing will be pivotal. Lilly’s Kisunla is also under regulatory review.